Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company is focusing on internal investments such as commissioning a new herbicide plant and setting up a new R&D facility. Capex for projects like the herbicide plant is ongoing but specific funding sources are not detailed. Management emphasizes operational growth, margin improvement, and capacity expansion, with plans to invest in new plants possibly on existing land or new land acquisitions. No direct statements about raising external capital through debt or equity were

Any current/future capex/capital investment/strategic investment?

New herbicide plant commissioning expected in Q4 FY2021, with phased ramp-up to full capacity in about 2 years. Targeted revenue from herbicide plant: Rs. 150-200 Crores within 2 years of commissioning. New state-of-the-art R&D facility under construction, expected to significantly increase R&D capabilities (5x increase), facilitating contract research and process intensification. Plans to hire 100-110 people initially for new R&D facility, potentially increasing with capacity utilization. Capacity expansion options include adding more reactors in the new plant and de-bottlenecking existing pl

Future growth expectations in sales/revenue/volumes?

Targeting a CAGR of 20% in bottom-line growth while maintaining margins despite price fluctuations. Current blended volume growth is approximately 15% to 20%, with domestic volumes growing around 60% YoY and exports around 40%. Domestic and export sales are roughly split 50:50, with domestic growth slightly outpacing exports recently. New R&D facility commissioning expected to increase capability, enabling rollout of 4-6 products per year versus 2 currently, accelerating growth. Expansion plans include adding multipurpose plants roughly every 1 to 1.5 years to meet demand. New herbic

Future growth expectations in earnings/operating earnings/profits/EPS?

Astec LifeSciences targets a compounded annual growth rate (CAGR) of 20% in bottomline/profits. EBITDA margins are expected to improve from 20% to 25% over time. The new R&D facility will significantly enhance capabilities, enabling rollout of 4-6 new products annually (up from 2). Growth will be driven by higher-margin products through advanced chemistries like fluorination, organometallic, chiral, flow, and biochemistry. New multipurpose and herbicide plants will scale over 1-2 years to full capacity, contributing to revenue and margin expansion. The company plans phased capacity expansion,

Current/ Expected Orderbook/ Pending Orders?

Current new herbicide plant orders occupy about 30% of the plant capacity. Additional orders under negotiation could increase this utilization to approximately 80%. Several products are in the pipeline, expected to further boost orderbook and plant utilization. Existing plants have opportunities for debottlenecking and process intensification to increase throughput and create spare capacity for more projects. The company expects full booking of the new herbicide plant capacity over the next couple of years. Due to shipping delays, some orders were deferred but expected to catch up in Q4. The n

Astec LifesciencQ3 FY21Fertilizers & Agrochemicals

Astec Lifescienc Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.55Market Cap: ₹1.2K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Targeting a CAGR of 20% in bottom-line growth while maintaining margins despite price fluctuations.
Current blended volume growth is approximately 15% to 20%, with domestic volumes growing around 60% YoY and exports around 40%.
Domestic and export sales are roughly split 50:50, with domestic growth slightly outpacing exports recently.
New R&D facility commissioning expected to increase capability, enabling rollout of 4-6 products per year versus 2 currently, accelerating growth.
Expansion plans include adding multipurpose plants roughly every 1 to 1.5 years to meet demand.
New herbicide plant commissioning in early 2021, expected to reach full capacity utilization and targeted revenue of ₹150-200 Crores within 2 years.
Export revenue to grow by exploring new geographies like Japan, though main markets remain the same.
Increased focus on higher margin products and intensified process improvements anticipated to drive revenue and margin expansion.

Margin guidance

Category 1

Astec LifeSciences targets a compounded annual growth rate (CAGR) of 20% in bottomline/profits.
EBITDA margins are expected to improve from 20% to 25% over time.
The new R&D facility will significantly enhance capabilities, enabling rollout of 4-6 new products annually (up from 2).
Growth will be driven by higher-margin products through advanced chemistries like fluorination, organometallic, chiral, flow, and biochemistry.
New multipurpose and herbicide plants will scale over 1-2 years to full capacity, contributing to revenue and margin expansion.
The company plans phased capacity expansion, possibly establishing a new multipurpose plant every 1-1.5 years.
Herbicide plant EBITDA margins expected over 20%, with gross margins around 50%.
Stable EBITDA margin guidance of 19%-20% sustainable over full year, aiming for gradual improvement towards 25%.

See what Astec Lifescienc management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The company is focusing on internal investments such as commissioning a new herbicide plant and setting up a new R&D facility.
Capex for projects like the herbicide plant is ongoing but specific funding sources are not detailed.
Management emphasizes operational growth, margin improvement, and capacity expansion, with plans to invest in new plants possibly on existing land or new land acquisitions.
No direct statements about raising external capital through debt or equity were discussed during the call.

Order book

Yes

Current new herbicide plant orders occupy about 30% of the plant capacity.
Additional orders under negotiation could increase this utilization to approximately 80%.
Several products are in the pipeline, expected to further boost orderbook and plant utilization.
Existing plants have opportunities for debottlenecking and process intensification to increase throughput and create spare capacity for more projects.
The company expects full booking of the new herbicide plant capacity over the next couple of years.
Due to shipping delays, some orders were deferred but expected to catch up in Q4.
The new R&D facility will enhance capacity to handle more projects and support incremental order intake.

See what Astec Lifescienc management said on order book — free account, 30 seconds.

Capex plans

Yes

New herbicide plant commissioning expected in Q4 FY2021, with phased ramp-up to full capacity in about 2 years.
Targeted revenue from herbicide plant: Rs. 150-200 Crores within 2 years of commissioning.
New state-of-the-art R&D facility under construction, expected to significantly increase R&D capabilities (5x increase), facilitating contract research and process intensification.
Plans to hire 100-110 people initially for new R&D facility, potentially increasing with capacity utilization.
Capacity expansion options include adding more reactors in the new plant and de-bottlenecking existing plants.
Backward integration underway to reduce reliance on China for raw materials, with some products already commissioned for local supply.
Management is scouting for new land in Gujarat for potential greenfield projects to put up more multipurpose plants in the future.

Track Astec Lifescienc — get its next earnings analysis in your feed

How does Astec Lifescienc rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisAstec Lifescienc

Rev 2Mar 1

See where Astec Lifescienc sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Astec Lifescienc rank in Fertilizers & Agrochemicals?

Compare Astec Lifescienc against every Fertilizers & Agrochemicals company (Q3 FY21) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Astec Lifescienc's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Best Agrolife Ltd (Q2 FY27)
Revenue from operations for Q2 FY27 is ₹407 crore, reflecting a year-on-year decline of 21%. Key results statement takeaways from Best Agrolife Ltd's Q2 FY27 ea
Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear

Compare:vs Coromandel Inter vs F A C T vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →